FDA re­jects Bio­con and Vi­a­tris' Avastin biosim­i­lar af­ter in­spec­tion ques­tion marks

Af­ter the FDA found mul­ti­ple is­sues at Bio­con’s man­u­fac­tur­ing fa­cil­i­ties in Malaysia and In­dia, the agency has shot down Bio­con and Vi­a­tris’ biosim­i­lar to Avastin …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER